Literature DB >> 1855284

Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain.

H Reiber1, P Lange.   

Abstract

Specific antibody synthesis in brain could be detected with maximal sensitivity by combining an advanced enzyme immunoassay with a sophisticated evaluation method that involves calculating the ratio between the cerebrospinal fluid (CSF)/serum quotients for specific antibodies (Qspec) and total IgG (QIgG). This Antibody Index (AI = Qspec/QIgG) discriminates between a blood-derived and a pathological, brain-derived specific antibody fraction in CSF and takes into account individual changes in blood/CSF barrier function. For local synthesis of polyclonal IgG in the central nervous system (QIgG greater than QLim), we propose the correction AI = Qspec/QLim (QLim represents that IgG fraction in CSF originating only from blood, calculated from the individual albumin quotient of a single patient). The normal reference range for the AI was between 0.7 and 1.3 (n = 250 control patients for each antibody species). Values of AI greater than or equal to 1.5 indicated a local specific antibody synthesis in the central nervous system. Sensitivity and precision were greatest if we analyzed the virus-specific antibodies in CSF and serum simultaneously with an enzyme immunoassay in continuous concentrations (arbitrary units) instead of titer steps. We have applied the method successfully to antibodies to measles, rubella, herpes simplex, varicella-zoster, human immunodeficiency virus (HIV), and cytomegalovirus, and to anti-Toxoplasma or -Borrelia antibodies. Clinical relevance is demonstrated for an acute zoster virus infection (monospecific response), chronic diseases such as HIV encephalitis with acute opportunistic Toxoplasma infection, and multiple sclerosis (secondary polyspecific response).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855284

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  103 in total

1.  Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Authors:  J Kuhle; R Gosert; R Bühler; T Derfuss; R Sutter; O Yaldizli; E-W Radue; C Ryschkewitsch; E O Major; L Kappos; S Frank; H H Hirsch
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

Review 2.  [Differential diagnosis of chronic inflammatory diseases of the central nervous system. Cerebrospinal fluid diagnosis and immunological parameters].

Authors:  D Reske; H-F Petereit
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

3.  Hypoglycorrhachia in herpes zoster associated encephalitis of an immunocompetent young male: an unusual presentation.

Authors:  Chun Wing Chan; Kin Ming Tam; Wing Kin To; Tin Chu Law; Wai Keung Kwan
Journal:  J Neurol       Date:  2005-04-04       Impact factor: 4.849

4.  IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment.

Authors:  H Prüss; M Höltje; N Maier; A Gomez; R Buchert; L Harms; G Ahnert-Hilger; D Schmitz; C Terborg; U Kopp; C Klingbeil; C Probst; S Kohler; J M Schwab; W Stoecker; J Dalmau; K P Wandinger
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

5.  Cerebrospinal-fluid profile in neuroborreliosis and its diagnostic significance.

Authors:  J Bednárova
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

6.  Humoral immune responses in patients with Lyme neuroborreliosis.

Authors:  Tjasa Cerar; Katarina Ogrinc; Franc Strle; Eva Ruzić-Sabljić
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

Review 7.  Subacute sclerosing panencephalitis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

8.  No evidence of Borna disease virus-specific antibodies in multiple sclerosis patients in Germany.

Authors:  B Kitze; S Herzog; P Rieckmann; S Poser; J Richt
Journal:  J Neurol       Date:  1996-09       Impact factor: 4.849

9.  Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms.

Authors:  Enrico Fainardi; Massimiliano Castellazzi; Carmine Tamborino; Silva Seraceni; Maria Rosaria Tola; Enrico Granieri; Carlo Contini
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

10.  Intrathecal immune response and virus-specific immunoglobulin M antibodies in laboratory diagnosis of acute poliomyelitis.

Authors:  M Roivainen; M Agboatwalla; M Stenvik; T Rysä; D S Akram; T Hovi
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.